Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00223951 · ClinicalTrials.gov registry record · Phase 3
Safety Study of Ophthalmic Solution in Healthy, Normal Volunteers
A Phase 3 study of Healthy Volunteers Eligible for Study; Drug Being Developed for Allergic Conjunctivitis, sponsored by Vistakon Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 900
- Enrollment target
- 6
- Study locations
NCT00223951: Completed Phase 3 study of Healthy Volunteers Eligible for Study; Drug Being Developed for Allergic Conjunctivitis, sponsored by Vistakon Pharmaceuticals.
NCT00223951 is a Phase 3 study of Healthy Volunteers Eligible for Study; Drug Being Developed for Allergic Conjunctivitis that has completed, run by Vistakon Pharmaceuticals. The registered enrollment target is 900 participants, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (17% higher). The trial reports 6 study locations across 6 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00223951, a Phase 3 study of Healthy Volunteers Eligible for Study; Drug Being Developed for Allergic Conjunctivitis, has completed, sponsored by Vistakon Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 900 participants
- Enrollment target
- 6
- Study locations
Study Summary
The purpose of this study is to evaluate the safety of R89674 0.25% ophthalmic solution in healthy normal volunteers
Conditions Studied
Interventions
- DRUG R89674 (generic name not yet established)
Study Locations (6)
Arizona
- - Phoenix
Maryland
- - Bel Air
Massachusetts
- - North Andover
Nevada
- - Las Vegas
North Carolina
- - Charlotte
Pennsylvania
- - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 900 participants |
| Start Date | 2005-09 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00223951
The ClinicalTrials.gov registry entry for NCT00223951 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 900 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (17% higher). The listed sponsor is Vistakon Pharmaceuticals, which has 13 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Healthy Volunteers Eligible for Study; Drug Being Developed for Allergic Conjunctivitis appearing as the primary indexed condition, and to 1 intervention - of which R89674 (generic name not yet established) is the first listed.
NCT00223951 reports 6 study locations spanning 6 distinct geographic areas - top geographies include Arizona, Maryland, Massachusetts.
Frequently Asked Questions
What is clinical trial NCT00223951 about?
NCT00223951 is a clinical study titled "Safety Study of Ophthalmic Solution in Healthy, Normal Volunteers". The purpose of this study is to evaluate the safety of R89674 0.25% ophthalmic solution in healthy normal volunteers
What is the current status of trial NCT00223951?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 900 participants. The study started on 2005-09.
What conditions does trial NCT00223951 study?
This clinical trial studies the following conditions: Healthy Volunteers Eligible for Study; Drug Being Developed for Allergic Conjunctivitis.
What interventions are being tested in trial NCT00223951?
The interventions under investigation include: R89674 (generic name not yet established) (DRUG).
Who is sponsoring clinical trial NCT00223951?
This trial is sponsored by Vistakon Pharmaceuticals, which has 13 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00223951 being conducted?
This trial has 6 study locations across Arizona, Maryland, Massachusetts, Nevada, North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.